BRAF and melanoma: Both colorectal cell lines and the melanoma cell line LOX were sensitive to dasatinib (log(GI50) between −7.908 and −7.657 in NCI-TPW), whereas many other melanoma cell lines with BRAF V600E were resistant to dasatinib (log(GI50) close to −5; Figure S5).